The concept of "risk sharing" is a new idea that was in many cases discarded during the managed care backlash. But now that old idea is getting new attention among pharmaceutical and biotech companies as part of the larger effort to control healthcare costs. This article from the Biotechnology Healthcare Journal examines the new risk sharing and includes perspective from Milliman principals Bruce Pyenson and Kate Fitch.